Effect of the nanoliposomal formulations of rifampin and N-acetyl cysteine on staphylococcus epidermidis biofilm

Document Type : Research Paper

Authors

1 School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

2 Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

3 Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Objective(s): Staphylococcus epidermidis is a common cause of medical device-associated infections due to biofilm formation, and its elimination is extremely challenging. Although rifampin efficacy against S. epidermidis biofilms has been confirmed, its use as a single agent may lead to resistance. As such, it is assumed that the combination of rifampin and N-acetylcysteine (NAC) could exert additive effects as a mucolytic agent. The present study aimed to use a liposomal system for the delivery of these compounds to bacterial biofilm.
Materials and Methods: Liposomal formulations were prepared using the dehydration-rehydration method and characterized in terms of the size, zeta potential, and encapsulation efficacy. In addition, the ability of various formulations in the eradication of bacterial biofilm and inhibition of biofilm formation was assessed based on the optical density ratio.
Results: The zeta potential of the liposomes was positive, and the mean size of these liposomal formulations was less than 200 nanometers. Liposomal rifampin was the most effective formulation against S. epidermidis, and the anti-biofilm activity of most of the formulations was concentration-dependent and time-dependent.
Conclusion: According to the results, the rifampin-loaded liposomes were effective against S. epidermidis biofilm formation.

Keywords

References

1.Kloos WE, Bannerman TL. Update on clinical significance of coagulase-negative staphylococci. Clin Microbiol Rev. 1994; 7(1): 117-140.
2.Khameneh B, Diab R, Ghazvini K, Fazly Bazzaz BS. Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them. Microb Pathog. 2016; 95 :32-42.
3.McCann MT, Gilmore BF, Gorman SP. Staphylococcus epidermidis device‐related infections: pathogenesis and clinical management. J Pharm Pharmacol. 2008; 60(12): 1551-1571.
4.Costerton WJ, Montanaro L, Balaban N, Arciola CR. Prospecting gene therapy of implant infections. Int J Artif Organs. 2009; 32(9): 689-695.
5.Perez-Giraldo C, Rodriguez-Benito A, Moran F, Hurtado C, Blanco M, Gomez-Garcia A. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. J Antimicrob Chemother. 1997; 39(5): 643-646.
6.Stey C, Steurer J, Bachmann S, Medici T, Tramer M. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J. 2000; 16(2): 253-262.
7.Olofsson A-C, Hermansson M, Elwing H. N-acetyl-L-cysteine affects growth, extracellular polysaccharide production, and bacterial biofilm formation on solid surfaces. Appl Environ Microbiol. 2003; 69(8): 4814-4822.
8.Moghadas-Sharif N, Fazly Bazzaz BS, Khameneh B, Malaekeh-Nikouei B. The effect of nanoliposomal formulations on Staphylococcus epidermidis biofilm. Drug Dev Ind Pharm. 2015; 41(3): 445-450.
9.Monzón M, Oteiza C, Leiva J, Amorena B. Synergy of different antibiotic combinations in biofilms of Staphylococcus epidermidis. Journal of Antimicrobial Chemotherapy. 2001; 48(6): 793-801.
10.Fazly Bazzaz BS, Khameneh B, Zarei H, Golmohammadzadeh S. Antibacterial efficacy of rifampin loaded solid lipid nanoparticles against Staphylococcus epidermidis biofilm. Microb Pathog. 2016; 93: 137-144.
11.Cheow WS, Hadinoto K. Lipid-polymer hybrid nanoparticles with rhamnolipid-triggered release capabilities as anti-biofilm drug delivery vehicles. Particuology. 2012; 10(3): 327-333.
12.Diab R, Khameneh B, Joubert O, Duval R. Insights in Nanoparticle-Bacterium Interactions: New Frontiers to Bypass Bacterial Resistance to Antibiotics. Curr Pharm Des. 2015; 21(28): 4095-4105.
13.Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm. 1997; 154(2): 123-140.
14.Kim H-J, Gias ELM, Jones MN. The adsorption of cationic liposomes to Staphylococcus aureus biofilms. Colloids Surf A Physicochem Eng Asp. 1999; 149(1-3): 561-570.
15.Khameneh B, Iranshahy M, Ghandadi M, Ghoochi Atashbeyk D, Fazly Bazzaz BS, Iranshahi M. Investigation of the antibacterial activity and efflux pump inhibitory effect of co-loaded piperine and gentamicin nanoliposomes in methicillin-resistant Staphylococcus aureus. Drug Dev Ind Pharm. 2015; 41(6): 989-994.
16.Atashbeyk DG, Khameneh B, Tafaghodi M, Fazly Bazzaz BS. Eradication of methicillin-resistant Staphylococcus aureus infection by nanoliposomes loaded with gentamicin and oleic acid. Pharm Biol. 2014; 52(11): 1423-1428.
17.Forier K, Messiaen AS, Raemdonck K, Nelis H, De Smedt S, Demeester J, Coenye T, Braeckmans K. Probing the size limit for nanomedicine penetration into Burkholderia multivorans and Pseudomonas aeruginosa biofilms. J Control Release. 2014; 195: 21-28.
18.Sugano M, Morisaki H, Negishi Y, Endo-Takahashi Y, Kuwata H, Miyazaki T, Yamamoto M. Potential effect of cationic liposomes on interactions with oral bacterial cells and biofilms. J Liposome Res. 2016; 26(2): 156-162.
19.Nogueira E, Gomes AC, Preto A, Cavaco-Paulo A. Design of liposomal formulations for cell targeting. Colloids Surf B Biointerfaces. 2015; 136: 514-526.
20.Chiesa E, Monti L, Paganini C, Dorati R, Conti B, Modena T, Rossi A, Genta I. Polyethylene Glycol-Poly-Lactide-co-Glycolide Block Copolymer-Based Nanoparticles as a Potential Tool for Off-Label Use of N-Acetylcysteine in the Treatment of Diastrophic Dysplasia. J Pharm Sci. 2017; 106(12): 3631-3641.
21.Waitz JA. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: National Committee for Clinical Laboratory Standards; 1990.
22.Pitts B, Hamilton MA, Zelver N, Stewart PS. A microtiter-plate screening method for biofilm disinfection and removal. J Microbiol Methods. 2003; 54(2): 269-276.
23.Gomez-Junyent J, Benavent E, Sierra Y, El Haj C, Soldevila L, Torrejon B, Rigo-Bonnin R, Tubau F, Ariza J, Murillo O. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model. Int J Antimicrob Agents. 2019; 53(5): 612-619.
24.Liu L, Li JH, Zi SF, Liu FR, Deng C, Ao X, Zhang P. AgNP combined with quorum sensing inhibitor increased the antibiofilm effect on Pseudomonas aeruginosa. Appl Microbiol Biotechnol. 2019; 103(15): 6195-6204.
25.Zheng Z, Stewart PS. Penetration of rifampin through Staphylococcus epidermidis biofilms. Antimicrob Agents Chemother. 2002; 46(3): 900-903.
26.Cerca N, Martins S, Cerca F, Jefferson KK, Pier GB, Oliveira R, Azeredo J. Comparative assessment of antibiotic susceptibility of coagulase-negative staphylococci in biofilm versus planktonic culture as assessed by bacterial enumeration or rapid XTT colorimetry. Journal of Antimicrobial Chemotherapy. 2005; 56(2): 331-336.
27.Monzón M, Oteiza C, Leiva J, Lamata M, Amorena B. Biofilm testing of Staphylococcus epidermidis clinical isolates: low performance of vancomycin in relation to other antibiotics. Diagn Microbiol Infect Dis. 2002; 44(4): 319-324.
28.Monzón M, Oteiza C, Leiva J, Amorena B. Synergy of different antibiotic combinations in biofilms of Staphylococcus epidermidis. J Antimicrob Chemother. 2001; 48(6): 793-801.
29.Leite B, Gomes F, Teixeira P, Souza C, Pizzolitto E, Oliveira R. Staphylococcus epidermidis biofilms control by N-acetylcysteine and rifampicin. Am J Ther. 2013; 20(4): 322-328.
30.Aslam S, Trautner BW, Ramanathan V, Darouiche RO. Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters. Antimicrob Agents Chemother. 2007; 51(4): 1556-1558.
31.Ahmed K, Muiruri PW, Jones GH, Scott MJ, Jones MN. The effect of grafted poly (ethylene glycol) on the electrophoretic properties of phospholipid liposomes and their adsorption to bacterial biofilms. Colloids Surf A Physicochem Eng Asp. 2001; 194(1-3): 287-296.
Nanomedicine Journal
Volume 7, Issue 2
April 2020
Pages 131-137

Files

Share

How to cite

Statistics